{"id":4321,"date":"2023-07-10T10:57:34","date_gmt":"2023-07-10T02:57:34","guid":{"rendered":"https:\/\/regask.com\/?p=4321"},"modified":"2024-09-25T03:59:26","modified_gmt":"2024-09-24T19:59:26","slug":"medicamentos-compuestos-de-la-fda-al-por-mayor","status":"publish","type":"post","link":"https:\/\/regask.com\/es\/fda-compounded-drugs-wholesaling\/","title":{"rendered":"La FDA de EE. UU. ofrece recomendaciones sobre la prohibici\u00f3n legal de\u2026"},"content":{"rendered":"
\n
\n
\n
\n
\n

Seg\u00fan la FDA, este borrador de gu\u00eda describe la interpretaci\u00f3n de la FDA y las pol\u00edticas relacionadas con la prohibici\u00f3n de venta al por mayor en la secci\u00f3n 503B de la Ley FD&C (21 USC 353b). Este borrador de gu\u00eda tambi\u00e9n describe ejemplos de c\u00f3mo la FDA pretende aplicar la secci\u00f3n 503B de la disposici\u00f3n sobre venta al por mayor de la Ley FD&C.<\/p>\n

Contiene informaci\u00f3n sobre t\u00e9rminos clave, actividades prohibidas por la disposici\u00f3n de venta al por mayor, actividades no prohibidas, inspecciones y acciones regulatorias o de cumplimiento.<\/p>\n

Los comentarios electr\u00f3nicos o escritos sobre el proyecto de gu\u00eda deben enviarse a m\u00e1s tardar el 28 de agosto de 2023, para garantizar que la Agencia considere los comentarios sobre este proyecto de gu\u00eda antes de comenzar a trabajar en la versi\u00f3n final de la gu\u00eda.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n

\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n

Comun\u00edquese con RegASK para obtener m\u00e1s informaci\u00f3n sobre los cambios regulatorios en los EE. UU.\u00a0<\/a><\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n\n\t\tContacte con RegASK para m\u00e1s detalles<\/span>\n\t<\/a>\n\n\n\t\tLeer m\u00e1s<\/span>\n\t<\/a>\n\n

\n\n\t
\n\t\t\t\t
\n\t\t\t\n\t\t\t\n\n\t\tLea estudios de casos de la industria farmac\u00e9utica y biotecnol\u00f3gica<\/span>\n\t<\/a>\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n<\/div>\n
\n
\n
<\/div>\n<\/div>\n<\/div>","protected":false},"excerpt":{"rendered":"

Seg\u00fan la FDA, este borrador de gu\u00eda describe la interpretaci\u00f3n de la FDA y las pol\u00edticas relacionadas con la prohibici\u00f3n de venta al por mayor en la secci\u00f3n 503B de la Ley FD&C (21 USC 353b). Este borrador de gu\u00eda tambi\u00e9n describe ejemplos de c\u00f3mo la FDA pretende aplicar la secci\u00f3n 503B de la disposici\u00f3n de venta al por mayor de la Ley FD&C. Contiene informaci\u00f3n sobre t\u00e9rminos clave,\u2026<\/p>","protected":false},"author":39,"featured_media":4047,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[35],"tags":[40],"class_list":["post-4321","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pharma-biotech-latest-insights","tag-latest-insights"],"acf":[],"yoast_head":"\nFDA Recommendations on Compounded Drug Wholesaling | RegASK<\/title>\n<meta name=\"description\" content=\"The US FDA issues recommendations on the statutory prohibition on wholesaling for certain compounded drugs. Learn more with RegASK.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/regask.com\/es\/medicamentos-compuestos-de-la-fda-al-por-mayor\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"US FDA Provides Recommendations on the Statutory Prohibition on Wholesaling for Certain Compounded Drugs\" \/>\n<meta property=\"og:description\" content=\"The US FDA issues recommendations on the statutory prohibition on wholesaling for certain compounded drugs. Learn more with RegASK.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/regask.com\/es\/medicamentos-compuestos-de-la-fda-al-por-mayor\/\" \/>\n<meta property=\"og:site_name\" content=\"RegASK\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/RegASKRegulatoryAffairs\/\" \/>\n<meta property=\"article:published_time\" content=\"2023-07-10T02:57:34+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-09-24T19:59:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/regask.com\/wp-content\/uploads\/2022\/12\/Amendment-to-the-Clinical-Trials-Regulation-CTR-on-Investigational-Medicinal-Products-IMPs-Labelling.png\" \/>\n\t<meta property=\"og:image:width\" content=\"331\" \/>\n\t<meta property=\"og:image:height\" content=\"301\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Benoit Trouwaert\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@ASKRegASK\" \/>\n<meta name=\"twitter:site\" content=\"@ASKRegASK\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Benoit Trouwaert\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minuto\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/regask.com\\\/fda-compounded-drugs-wholesaling\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/regask.com\\\/fda-compounded-drugs-wholesaling\\\/\"},\"author\":{\"name\":\"Benoit Trouwaert\",\"@id\":\"https:\\\/\\\/regask.com\\\/#\\\/schema\\\/person\\\/c1d261e8dcf7b1c30b2c4f2c119df42d\"},\"headline\":\"US FDA Provides Recommendations on the Statutory Prohib…\",\"datePublished\":\"2023-07-10T02:57:34+00:00\",\"dateModified\":\"2024-09-24T19:59:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/regask.com\\\/fda-compounded-drugs-wholesaling\\\/\"},\"wordCount\":207,\"publisher\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/regask.com\\\/fda-compounded-drugs-wholesaling\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2022\\\/12\\\/Amendment-to-the-Clinical-Trials-Regulation-CTR-on-Investigational-Medicinal-Products-IMPs-Labelling.png\",\"keywords\":[\"Latest Insights\"],\"articleSection\":[\"Pharma and Biotech\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/regask.com\\\/fda-compounded-drugs-wholesaling\\\/\",\"url\":\"https:\\\/\\\/regask.com\\\/fda-compounded-drugs-wholesaling\\\/\",\"name\":\"FDA Recommendations on Compounded Drug Wholesaling | RegASK\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/regask.com\\\/fda-compounded-drugs-wholesaling\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/regask.com\\\/fda-compounded-drugs-wholesaling\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2022\\\/12\\\/Amendment-to-the-Clinical-Trials-Regulation-CTR-on-Investigational-Medicinal-Products-IMPs-Labelling.png\",\"datePublished\":\"2023-07-10T02:57:34+00:00\",\"dateModified\":\"2024-09-24T19:59:26+00:00\",\"description\":\"The US FDA issues recommendations on the statutory prohibition on wholesaling for certain compounded drugs. Learn more with RegASK.\",\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/regask.com\\\/fda-compounded-drugs-wholesaling\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/regask.com\\\/fda-compounded-drugs-wholesaling\\\/#primaryimage\",\"url\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2022\\\/12\\\/Amendment-to-the-Clinical-Trials-Regulation-CTR-on-Investigational-Medicinal-Products-IMPs-Labelling.png\",\"contentUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2022\\\/12\\\/Amendment-to-the-Clinical-Trials-Regulation-CTR-on-Investigational-Medicinal-Products-IMPs-Labelling.png\",\"width\":331,\"height\":301,\"caption\":\"Amendment To The Clinical Trials Regulation (ctr) On Investigational Medicinal Products (imps) Labelling\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/regask.com\\\/#website\",\"url\":\"https:\\\/\\\/regask.com\\\/\",\"name\":\"RegASK\",\"description\":\"The Regulatory AI Operating System for High-Performing Teams\",\"publisher\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/regask.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/regask.com\\\/#\\\/schema\\\/person\\\/c1d261e8dcf7b1c30b2c4f2c119df42d\",\"name\":\"Benoit Trouwaert\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Recomendaciones de la FDA sobre la venta al por mayor de medicamentos compuestos | RegASK","description":"La FDA de los EE. UU. emite recomendaciones sobre la prohibici\u00f3n legal de la venta al por mayor de determinados medicamentos compuestos. Obtenga m\u00e1s informaci\u00f3n en RegASK.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/regask.com\/es\/medicamentos-compuestos-de-la-fda-al-por-mayor\/","og_locale":"es_ES","og_type":"article","og_title":"US FDA Provides Recommendations on the Statutory Prohibition on Wholesaling for Certain Compounded Drugs","og_description":"The US FDA issues recommendations on the statutory prohibition on wholesaling for certain compounded drugs. Learn more with RegASK.","og_url":"https:\/\/regask.com\/es\/medicamentos-compuestos-de-la-fda-al-por-mayor\/","og_site_name":"RegASK","article_publisher":"https:\/\/www.facebook.com\/RegASKRegulatoryAffairs\/","article_published_time":"2023-07-10T02:57:34+00:00","article_modified_time":"2024-09-24T19:59:26+00:00","og_image":[{"width":331,"height":301,"url":"https:\/\/regask.com\/wp-content\/uploads\/2022\/12\/Amendment-to-the-Clinical-Trials-Regulation-CTR-on-Investigational-Medicinal-Products-IMPs-Labelling.png","type":"image\/png"}],"author":"Benoit Trouwaert","twitter_card":"summary_large_image","twitter_creator":"@ASKRegASK","twitter_site":"@ASKRegASK","twitter_misc":{"Written by":"Benoit Trouwaert","Est. reading time":"1 minuto"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/regask.com\/fda-compounded-drugs-wholesaling\/#article","isPartOf":{"@id":"https:\/\/regask.com\/fda-compounded-drugs-wholesaling\/"},"author":{"name":"Benoit Trouwaert","@id":"https:\/\/regask.com\/#\/schema\/person\/c1d261e8dcf7b1c30b2c4f2c119df42d"},"headline":"US FDA Provides Recommendations on the Statutory Prohib…","datePublished":"2023-07-10T02:57:34+00:00","dateModified":"2024-09-24T19:59:26+00:00","mainEntityOfPage":{"@id":"https:\/\/regask.com\/fda-compounded-drugs-wholesaling\/"},"wordCount":207,"publisher":{"@id":"https:\/\/regask.com\/#organization"},"image":{"@id":"https:\/\/regask.com\/fda-compounded-drugs-wholesaling\/#primaryimage"},"thumbnailUrl":"https:\/\/regask.com\/wp-content\/uploads\/2022\/12\/Amendment-to-the-Clinical-Trials-Regulation-CTR-on-Investigational-Medicinal-Products-IMPs-Labelling.png","keywords":["Latest Insights"],"articleSection":["Pharma and Biotech"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/regask.com\/fda-compounded-drugs-wholesaling\/","url":"https:\/\/regask.com\/fda-compounded-drugs-wholesaling\/","name":"Recomendaciones de la FDA sobre la venta al por mayor de medicamentos compuestos | RegASK","isPartOf":{"@id":"https:\/\/regask.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/regask.com\/fda-compounded-drugs-wholesaling\/#primaryimage"},"image":{"@id":"https:\/\/regask.com\/fda-compounded-drugs-wholesaling\/#primaryimage"},"thumbnailUrl":"https:\/\/regask.com\/wp-content\/uploads\/2022\/12\/Amendment-to-the-Clinical-Trials-Regulation-CTR-on-Investigational-Medicinal-Products-IMPs-Labelling.png","datePublished":"2023-07-10T02:57:34+00:00","dateModified":"2024-09-24T19:59:26+00:00","description":"La FDA de los EE. UU. emite recomendaciones sobre la prohibici\u00f3n legal de la venta al por mayor de determinados medicamentos compuestos. Obtenga m\u00e1s informaci\u00f3n en RegASK.","inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/regask.com\/fda-compounded-drugs-wholesaling\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/regask.com\/fda-compounded-drugs-wholesaling\/#primaryimage","url":"https:\/\/regask.com\/wp-content\/uploads\/2022\/12\/Amendment-to-the-Clinical-Trials-Regulation-CTR-on-Investigational-Medicinal-Products-IMPs-Labelling.png","contentUrl":"https:\/\/regask.com\/wp-content\/uploads\/2022\/12\/Amendment-to-the-Clinical-Trials-Regulation-CTR-on-Investigational-Medicinal-Products-IMPs-Labelling.png","width":331,"height":301,"caption":"Amendment To The Clinical Trials Regulation (ctr) On Investigational Medicinal Products (imps) Labelling"},{"@type":"WebSite","@id":"https:\/\/regask.com\/#website","url":"https:\/\/regask.com\/","name":"RegASK","description":"El sistema operativo de IA regulatoria para equipos de alto rendimiento","publisher":{"@id":"https:\/\/regask.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/regask.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Person","@id":"https:\/\/regask.com\/#\/schema\/person\/c1d261e8dcf7b1c30b2c4f2c119df42d","name":"Benoit Trouwaert"}]}},"_links":{"self":[{"href":"https:\/\/regask.com\/es\/wp-json\/wp\/v2\/posts\/4321","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/regask.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/regask.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/regask.com\/es\/wp-json\/wp\/v2\/users\/39"}],"replies":[{"embeddable":true,"href":"https:\/\/regask.com\/es\/wp-json\/wp\/v2\/comments?post=4321"}],"version-history":[{"count":0,"href":"https:\/\/regask.com\/es\/wp-json\/wp\/v2\/posts\/4321\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/regask.com\/es\/wp-json\/wp\/v2\/media\/4047"}],"wp:attachment":[{"href":"https:\/\/regask.com\/es\/wp-json\/wp\/v2\/media?parent=4321"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/regask.com\/es\/wp-json\/wp\/v2\/categories?post=4321"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/regask.com\/es\/wp-json\/wp\/v2\/tags?post=4321"}],"curies":[{"name":"Gracias","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}